Landscape review of global real-world data sources for studying medication use in pregnancy and lactation that support regulatory decision making

被引:2
作者
Davis, Kourtney [1 ]
Yost, Emily [1 ,6 ]
Brauneis, Jacquelyne [2 ]
Krumme, Alexis [1 ]
Geldhof, Anja [3 ]
Tuck, Astrud [4 ]
Sylvester, Shirley [5 ]
Ephross, Sara [2 ]
机构
[1] Janssen Res & Dev LLC, Global Epidemiol, Raritan, NJ USA
[2] Syneos Hlth, Real World & Late Phase, Morrisville, NC USA
[3] Janssen Bol BV, Med Affairs, Leiden, Netherlands
[4] Janssen Res & Dev LLC, Data Sci, New Brunswick, NJ USA
[5] Johnson & Johnson, Global Publ Hlth, Zug, Switzerland
[6] Janssen Res & Dev LLC, Dept Epidemiol, 1125 Trenton Harbourton Rd, Titusville, NJ 08560 USA
关键词
breastfeeding; mother-infant; pharmacoepidemiology; pregnancy; real-world data;
D O I
10.1002/pds.5711
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Purpose: Most pregnant people take at least one medication during gestation or while breastfeeding, however data are lacking on the safety of medication use in these populations. We conducted a landscape review of real-world data sources specific to medication use in pregnancy and breastfeeding populations that have met, or have potential to meet, health authorities' requirements for post-authorization safety studies.Methods: A 2-phase approach identified data sources from literature, publicly available registers of non-interventional post-authorization studies of pregnant women, existing database inventories, and emerging data sources known to the authors.Results: Required key attributes were assessed according to current regulatory guidance, resulting in selection of 49 suitable data sources. All global regions were represented, with North America (37%) and Europe (33%) most common; 12% of the data sources included pregnancy information from low-to middle-income countries. Administrative healthcare claims (25%) and electronic healthcare records (21%) comprised the largest types of data sources. Across data sources, 53% were managed by national or regional governments, 27% by industry, and 20% by academic institutions. Maternal age, diagnoses, prenatal care, and reproductive history were available in most, whereas fewer included demographic data (e.g., race/ethnicity). Breastfeeding data were collected in 37% of the final data sources.Conclusion: We conducted a systematic approach to data source evaluation of pregnancy and breastfeeding to be used as a resource for investigators to consider when designing pregnancy-related research studies to satisfy regulatory requirements.
引用
收藏
页数:22
相关论文
共 50 条
  • [21] Rethinking Medication Safety in Pregnancy: How Target Trial Emulation and Real-World Data Bridge the Evidence Gap
    Hu, Yanhong Jessika
    Said, Joanne M.
    Cheong, Jeanie L. Y.
    JOURNAL OF CLINICAL EPIDEMIOLOGY, 2025, 181
  • [22] Understanding the landscape and promoting the use of guides for real-world study: a scoping review
    Qi, Yana
    Zhao, Kai
    Chen, Ningsu
    Xue, Xinyu
    Yu, Jiajie
    Sun, Xin
    JOURNAL OF CLINICAL EPIDEMIOLOGY, 2024, 176
  • [23] Use of Routinely Collected "Real-world" Data for the Postlicensure Safety Assessment of Vaccination During Pregnancy
    Regan, Annette K.
    Rowe, Stacey L.
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2025, 44 (02) : S108 - S110
  • [24] What, Where, and How to Collect Real-World Data and Generate Real-World Evidence to Support Drug Reimbursement Decision-Making in Asia: A reflection Into the Past and A Way Forward
    Kc, Sarin
    Lin, Lydia Wenxin
    Bayani, Diana Beatriz Samson
    Zemlyanska, Yaroslava
    Adler, Amanda
    Ahn, Jeonghoon
    Chan, Kelvin
    Choiphel, Dechen
    Genuino-Marfori, Anne Julienne
    Kearney, Brendon
    Liu, Yuehua
    Nakamura, Ryota
    Pearce, Fiona
    Prinja, Shankar
    Pwu, Raoh-Fang
    Shafie, Arsul Akmal
    Sui, Binyan
    Suwantika, Auliya
    Tunis, Sean
    Wu, Hui-Min
    Zalcberg, John
    Zhao, Kun
    Isaranuwatchai, Wanrudee
    Teerawattananon, Yot
    Wee, Hwee-Lin
    INTERNATIONAL JOURNAL OF HEALTH POLICY AND MANAGEMENT, 2023, 12
  • [25] Real-world evidence to support health technology assessment and payer decision making: is it now or never?
    Murphy, Linda A.
    Akehurst, Ron
    Cunningham, David
    de Pouvourville, Gerard
    Sola-Morales, Oriol
    INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2025, 41 (01)
  • [26] Use of real-world evidence from healthcare utilization data to evaluate drug safety during pregnancy
    Huybrechts, Krista F.
    Bateman, Brian T.
    Hernandez-Diaz, Sonia
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2019, 28 (07) : 906 - 922
  • [27] Big Data and Real-World Data based Cost-Effectiveness Studies and Decision-making Models: A Systematic Review and Analysis
    Lu, Z. Kevin
    Xiong, Xiaomo
    Lee, Taiying
    Wu, Jun
    Yuan, Jing
    Jiang, Bin
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [28] Multiple Perspectives on the Need for Real-World Evidence to Inform Regulatory and Health Technology Assessment Decision-Making: Scoping Review and Stakeholder Interviews
    Jansen, Marieke S.
    Dekkers, Olaf M.
    le Cessie, Saskia
    Hooft, Lotty
    Gardarsdottir, Helga
    de Boer, Anthonius
    Groenwold, Rolf H. H.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2025, 34 (01)
  • [29] Can we use existing guidance to support the development of robust real-world evidence for health technology assessment/payer decision-making?
    Capkun, Gorana
    Corry, Sorcha
    Dowling, Oonagh
    Kolaei, Fatemeh Asad Zadeh Vosta
    Takyar, Shweta
    Furtado, Claudia
    Jonsson, Pall
    Kleinermans, Diane
    Lambert, Laurie
    Schiel, Anja
    Facey, Karen
    INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2022, 38 (01)
  • [30] Prevalence of comorbidities and concomitant medication use in acromegaly: analysis of real-world data from the United States
    Fleseriu, Maria
    Barkan, Ariel
    Schneider, Maria del Pilar
    Darhi, Yannis
    de Pierrefeu, Amicie
    Ribeiro-Oliveira, Antonio, Jr.
    Petersenn, Stephan
    Neggers, Sebastian
    Melmed, Shlomo
    PITUITARY, 2022, 25 (02) : 296 - 307